Within in one week, Indianapolis-based Eli Lilly hopes two oncology purchases will boost its cancer drug portfolio.
Eli Lilly has purchased two smaller companies in the past week that have oncology drugs in development. The Indianapolis-based company hopes the investments boost its cancer drug portfolio.
Last week Eli Lilly announced a $1.6 billion buyout of California-based ARMO BioScience for an immunotherapy drug. Immunotherapy treatments – which train the body to fight disease – have gained momentum recently.